Comprehensive genomic profiling of upper-tract and bladder urothelial carcinoma
Background Characterization of the different genomic alterations (GAs) in urothelial
carcinoma (UC), by site of origin, may identify contrasting therapeutic opportunities and …
carcinoma (UC), by site of origin, may identify contrasting therapeutic opportunities and …
Tumor mutational burden as a predictor of first-line immune checkpoint inhibitor versus carboplatin benefit in cisplatin-unfit patients with urothelial carcinoma
RP Graf, V Fisher, RSP Huang, O Hamdani… - JCO Precision …, 2022 - ascopubs.org
PURPOSE In real-world settings, patients with metastatic urothelial carcinoma (mUC) are
often more frail than clinical trials, underscoring an unmet need to identify patients who …
often more frail than clinical trials, underscoring an unmet need to identify patients who …
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer
M Rijnders, JA Nakauma-González… - Nature …, 2024 - nature.com
Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic
urothelial cancer (mUC), but therapeutic success at the individual patient level varies …
urothelial cancer (mUC), but therapeutic success at the individual patient level varies …
[HTML][HTML] Comprehensive molecular characterization of urothelial bladder carcinoma
Cancer Genome Atlas Research Network - Nature, 2014 - ncbi.nlm.nih.gov
Urothelial carcinoma of the bladder is a common malignancy that causes approximately
150,000 deaths per year worldwide. So far, no molecularly targeted agents have been …
150,000 deaths per year worldwide. So far, no molecularly targeted agents have been …
Comparison of tumor mutational burden (TMB) in relevant molecular subsets of metastatic urothelial cancer (MUC)
Background: Phase I and II studies suggest potential benefit with targeted therapy (TT)(eg,
FGFR3, ERBB2/3 and CDK4/6 inhibitors) in relevant molecular subsets of MUC. Given …
FGFR3, ERBB2/3 and CDK4/6 inhibitors) in relevant molecular subsets of MUC. Given …
Invasive bladder cancer: genomic insights and therapeutic promise
Invasive bladder cancer, for which there have been few therapeutic advances in the past 20
years, is a significant medical problem associated with metastatic disease and frequent …
years, is a significant medical problem associated with metastatic disease and frequent …
Genomic heterogeneity as a barrier to precision oncology in urothelial cancer
Precision oncology relies on the accurate molecular characterization of individual patients
with cancer at the time of treatment initiation. However, tumor molecular profiles are not …
with cancer at the time of treatment initiation. However, tumor molecular profiles are not …
Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor …
Although immune checkpoint inhibitors (ICIs) are increasingly used as second-line
treatments for urothelial cancer (UC), only a small proportion of patients respond. Therefore …
treatments for urothelial cancer (UC), only a small proportion of patients respond. Therefore …
[HTML][HTML] Emerging biomarkers and targeted therapies in urothelial carcinoma
P Mendiratta, P Grivas - Annals of Translational Medicine, 2018 - ncbi.nlm.nih.gov
The use of immunotherapy has revolutionized the management of patients with locally
advanced, unresectable, and metastatic urothelial carcinoma (UC); however, platinum …
advanced, unresectable, and metastatic urothelial carcinoma (UC); however, platinum …
The cancer genome atlas project in bladder cancer
A Rodriguez-Vida, SP Lerner, J Bellmunt - Genitourinary cancers, 2018 - Springer
Bladder cancer (BC) remains an aggressive disease with a poor prognosis, especially for
patients with metastatic disease who have a limited median overall survival of 14 months …
patients with metastatic disease who have a limited median overall survival of 14 months …